I agree that this site is using cookies. You can find further informations here.
X
Bringhen, S.
101  results:
Search for persons X
?
1

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-..:

Larocca, A. ; D'Agostino, M. ; Giuliani, N....
HemaSphere.  7 (2023)  S2 - p. 12-13 , 2023
Link: https://doi.org/10.1097/..
 
?
2

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH REL..:

Mateos, M ; Leleu, X ; Zamagni, E...
HemaSphere.  6 (2022)  - p. 24-25 , 2022
Link: https://doi.org/10.1097/..
 
?
3

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIB..:

D'Agostino, M. ; Bringhen, S. ; Ria, R....
HemaSphere.  6 (2022)  - p. 201-202 , 2022
Link: https://doi.org/10.1097/..
 
?
4

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS W..:

Maiolino, A ; Hajek, R ; Jelinek, T...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S197-S198 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Echocardiographic systolic and diastolic function alteratio..:

Mingrone, G ; Astarita, A ; Maffei, I...
European Heart Journal - Cardiovascular Imaging.  22 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
6

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS ..:

Capra, M.E.Z. ; Beksac, M. ; Richardson, P.G....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 263-264 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Prevention, monitoring and treatment of cardiovascular adve..:

Bringhen, S. ; Milan, A. ; D'Agostino, M....
Journal of Internal Medicine.  286 (2019)  1 - p. 63-74 , 2019
Link: https://doi.org/10.1111/..
 
?
8

Evaluation of Cardiovascular Toxicity Associated with Treat..:

Iannaccone, Andrea ; Bruno, G. ; Ravera, A....
High Blood Pressure & Cardiovascular Prevention.  25 (2018)  2 - p. 209-218 , 2018
Link: https://doi.org/10.1007/..
 
?
9

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, de..:

Bringhen, S ; D'Agostino, M ; De Paoli, L...
Leukemia.  32 (2017)  4 - p. 979-985 , 2017
Link: https://doi.org/10.1038/..
 
?
10

A phase 2 study of three low-dose intensity subcutaneous bo..:

Larocca, A ; Bringhen, S ; Petrucci, M T...
Leukemia.  30 (2016)  6 - p. 1320-1326 , 2016
Link: https://doi.org/10.1038/..
 
?
11

Optimal Sequential Therapy in First Line and First Relapse ..:

Offidani, M. ; Corvatta, L. ; Bringhen, S....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e278 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Early Mortality in Elderly Patients With Newly Diagnosed Mu..:

Larocca, A. ; Bringhen, S. ; Petrucci, M.T....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e42-e43 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Weekly Carfilzomib in combination with cyclophosphamide and..:

Bringhen, S. ; Gay, F. ; Rossi, D....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e70 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Lenalidomide-Dexamethasone or Melphalan-Lenalidomide-Predni..:

Magarotto, V. ; Bringhen, S. ; Musto, P....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e69 , 2015
Link: https://doi.org/10.1016/..
 
?
15

Previous thalidomide therapy may not affect lenalidomide re..:

Guglielmelli, T. ; Bringhen, S. ; Rrodhe, S....
European Journal of Cancer.  47 (2011)  6 - p. 814-818 , 2011
Link: https://doi.org/10.1016/..
 
1-15